BLOOD SCREENING MARKET ANALYSIS

Name: Blood Screening Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Blood Screening Market, by Technology (Nucleic acid amplification technology (NAT), ELISA, Immunoassays (IAs), Next Generation Sequencing, and Western Blotting), by Product Type (Reagents & kits and Instruments,), by End Users (Hospitals, Blood Banks, and Diagnostics laboratory), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Key Development

In July 2019, Abbott Laboratories, received the U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity s System. Alinity s System is designed to screen blood and plasma more efficiently in less space and also generate the test results consuming less tume and minimum human error.
In 2018, LifeCell International Pvt. Ltd launched RightStart, an integrated DNA-based screening for the diagnosis of more than 50 medical conditions among newborn patients.
In 2017, Clinical Genomics Pty Ltd, launched circulating tumor DNA (ctDNA) blood-based test for the detection of colorectal cancer.
In 2016, Hologic, Inc and Grifols, S.A being in a partnership agreement, received the US Food and Drug Administration (FDA) approval for its Procleix Zika virus blood screening assay.
In 2016, F. Hoffmann-La Roche Ltd, received US Food and Drug Administration (FDA) approval for its cobas MPX test applicable with analyzers like cobas 6800 and 8800 Systems for the detection of HIV-1, HIV-2, HBV and HCV.